A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Canc
A phase 3 trial of Pembrolizumab, Sacituzumab tirumotecan, Bevacizumab in cervical cancer, run by Merck Sharp & Dohme LLC, now recruiting.
Overview
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) is a phase 3 interventional study registered as NCT07216703 by Merck Sharp & Dohme LLC, with 1023 participants planned, started 2026-01-19 and due to reach its primary completion in 2031-10-29. Interventions recorded: Pembrolizumab, Sacituzumab Tirumotecan, Bevacizumab, Paclitaxel, Cisplatin. Conditions listed: Cervical Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participan
Shares Sacituzumab tirumotecan, Paclitaxel / nab-paclitaxel, Cisplatin, Merck & Co. (MSD).
- TrialPembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-287
Shares Sacituzumab tirumotecan, Paclitaxel / nab-paclitaxel, Merck & Co. (MSD), Carboplatin.
- TrialBAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer
Shares Bevacizumab, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.
- TrialStudy of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participan
Shares Paclitaxel / nab-paclitaxel, Cisplatin, Merck & Co. (MSD), Carboplatin.
- TrialA Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Sm
Shares Sacituzumab tirumotecan, Cisplatin, Merck & Co. (MSD), Carboplatin.
- TrialA Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
Shares Bevacizumab, Paclitaxel / nab-paclitaxel, Merck & Co. (MSD), Carboplatin.
- TrialA Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Carboplatin, Pembrolizumab.
- TrialA Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With
Shares Paclitaxel / nab-paclitaxel, Cisplatin, Merck & Co. (MSD), Carboplatin.